|
|
|
| Integrated solutions that evolve with you from research to commercialization. | Navigate therapy production complexities with solutions spanning every development stage. PrimePath is a comprehensive cell and gene portfolio including media and reagents, recombinant growth factors and proteins, specialty chemicals, critical assay materials, services, testing, and more. From discovery and research through clinical development to commercialization, the right partner matters. Discover how PrimePath supports your current and future needs at every phase of therapy development. |
|
|
|
|
By GlobalData | In conjunction with PharmSource, part of GlobalData, the first report of the year “Contract Manufacturing: Opportunities and Threats (CMOT) Report” is available now. The report identifies key events affecting CDMOs, including company acquisitions, product acquisitions, licenses, and approvals, late clinical product terminations, and FDA rejections. | |
|
|
| Detecting Particles In Biologic And CGT Drug Products | Webinar | Coriolis Pharma | Mitigate risk by identifying visible and subvisible particles in your pipeline. This webinar outlines characterization techniques essential for maintaining purity in cell and gene therapies. |
|
|
|
|
| Platform Optimization For AAV Manufacture Efficiency | Poster | By Chloe Fustinoni, F. Bennett, Mohine Alam, et al., Minaris Advanced Therapies | Discover the platform that demonstrates a 30-fold increase in AAV yields while cutting costs by 85%. Review the data on how this scalable approach improves capsid quality and manufacturing purity. |
|
|
|
| Complexities And Pitfalls In cGMP Tissue Sourcing | Infographic | Lonza | Procuring the “right human tissue” is fraught with misconceptions. Review the complex sourcing elements required to meet BLA standards and ensure consistent cell quality and count. |
|
|
| Key CMC Step For Cell Therapy IND Success | Article | Kincell Bio | Regulatory approval hinges on manufacturing consistency. Find the balance of the safety, quality, and potency benchmarks required to support a successful IND filing and subsequent clinical progression. |
|
|
| Maximize Starting Material Consistency | Infographic | Comprehensive Cell Solutions, A Business Unit Of NYBC Enterprises | By implementing an efficient characterization strategy, researchers can enhance the consistency of allogeneic cell therapy starting material, ultimately leading to improved clinical outcomes. |
|
|
| Capital Constraints In CDMO & Pharma M&A | Q&A | Vector BioMed | Tighter investment conditions are forcing a shift toward selective M&A and disciplined partnerships. Explore how current capital constraints are reshaping long-term outsourcing strategies. |
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
